



The 65th ASH Annual Meeting Abstracts

ONLINE PUBLICATION ONLY

613.ACUTE MYELOID LEUKEMIAS: CLINICAL AND EPIDEMIOLOGICAL

Prospective Real-World Outcomes of Acute Myeloid Leukemia

Volkan Karakus, Assoc Prof¹, Utku Iltar², Emel Merve Yenihayat³, Merve Gokcan Polat³, Serhat Celik, MD⁴, Umit Yavuz Malkan⁵, Guldane Cengiz Seval, MD⁶, Ali Dogan⁷, Aydan Akdeniz⁸, Ibrahim Ethem Pinar⁹, Demircan Ozdalci¹⁰, Idris Ince¹¹, Ramazan Erdem¹, Ozgur Mehtap³, Hakki Onur Kirkizlar¹², Murat Kacmaz¹³, Burak Devenci, MD¹⁴, Fatma Aykas¹, Gulden Korkmaz Akat¹⁵, Sureyya Yigit Kaya, MD¹⁶, Hacer Berna Afacan Ozturk¹⁷, Omur Sevindik, MD¹⁸, Ferda Can¹⁵, Demet Cekdemir¹⁹, Ceyda Aslan, MD²⁰, Hale Bulbul¹⁹, Zeynep Tugba Guven, MD²¹, Senem Maral¹⁸, Salih Sertac Durusoy²², Fatih Demirkan, Prof²³, Hakan Goker, Prof⁵, Fahir Ozkalemkas, Prof²⁴, Muzaffer Keklik⁴, Selami Kocak Toprak²⁵, Elcin Erdogan Yucel, MD²³, Unal Atas, MD¹, Inci Alacacioglu, Prof²³

¹Antalya Training and Research Hospital, Antalya, Turkey

²Akdeniz University Faculty of Medicine, Antalya, Turkey

³Kocaeli University Faculty of Medicine, Kocaeli, Turkey

⁴Erciyes University Faculty of Medicine, Kayseri, Turkey

⁵Hacettepe University Faculty of Medicine, Ankara, Turkey

⁶Ankara University School of Medicine, Hematology Department, Mamak, Turkey

⁷Van Yuzuncu Yil University Faculty of Medicine, Van, Turkey

⁸Mersin University Faculty of Medicine, Mersin, Turkey

⁹Uludag University Faculty of Medicine, Bursa, Turkey

¹⁰Suleyman Demirel University Hospital, Isparta, Turkey

¹¹Gaziantep Dr. Ersin Arslan Training and Research Hospital, Gaziantep, Turkey

¹²Trakya University Faculty of Medicine, Edirne, Turkey

¹³Hatay Mustafa Kemal University Faculty of Medicine, Hatay, Turkey

¹⁴Medstar Antalya Hospital, Antalya, Turkey

¹⁵Ankara City Hospital, Ankara, Turkey

¹⁶Celal Bayar University Faculty of Medicine, Manisa, Turkey

¹⁷University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

¹⁸Medipol University Hospital, Istanbul, Turkey

¹⁹Izmir Tepecik Training and Research Hospital, Izmir, Turkey

²⁰Kocaeli Derince Training and Research Hospital, Kocaeli, Turkey

²¹Niğde Training and Research Hospital, Niğde, Turkey

²²Sanko University Hospital, Gaziantep, Turkey

²³Dokuz Eylul University Faculty of Medicine, Izmir, Turkey

²⁴Bursa Uludag University Faculty of Medicine, Bursa, Turkey

²⁵Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey

Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large population-based cohort who were diagnosed and followed up in Turkey as a real-world data.

Methods: All AML adult patients who were recorded on the database of Turkish AML Registry project from 25 sites were included in this study if they were diagnosed before 1st of June 2022. Study approved by ethics committee and Ministry of Health of Turkey. Demographics and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented.

Results: A total of 906 patients were included in the study, 891 patients data accepted as adequate and underwent further evaluation. Median follow-up period was 12.0 (SD:26.6) months and 45.4% of the patients were female. Median age at the time of diagnosis was 58 (18-91). According to the FAB classification most common subtypes were M4 (23.6%), M2 (21.6%), M5 (16.8%) and M1 (13.5%) and AML, NOS (36.9%) is the most common type according to the WHO classification. Of the pa-

tients 60.8%, 24.7%, 14.5%, was intermediate, favorable and poor respectively considering AML risk stratification (ELN 2017) by genetics. Only 4.4% of the patients had extramedullary involvement. For the first induction 70.8% of the patients had received intensive regimens composing anthracyclines and ARA-C and for the first relapse 71.8%. ARA-C (71.7%) backbone and Azacitidine alone (13.4%) are the most used regimens, 10.5% and 22.5% underwent allo-HCT during the first and second induction respectively. Response rates obtained by the induction therapies were as follows; 61.7% CR (including 9.3% MLFS), 14.2% PR, 8.6% SD, 15.5% PD, the ratio was 59.7% and 24.3% for CR2 and PD respectively. Median overall survival has not been reached for the favorable risk group, were 16.2 months for the intermediate risk and 14.1 months for the poor risk group ($p < 0.001$) and 22.7 months for the entire population. Median progression free survival were 32.6 months for the favorable risk group, 12.7 months for the intermediate risk and 9.4 months for the poor risk group ($p < 0.001$) and 15.2 months for the entire population (Figure 1). COX regression analysis were performed for the prognostic factors of OS, univariate analysis performed with the parameters; age (< 60 and ≥ 60), FAB classification, ECOG, FLT3, NMP1, HCT were accepted as clinically significant covariates. First univariate then with the significant parameters ($p < 0.05$) multivariate COX regression analysis were performed. With the multivariate analysis age ($p: 0.005$, HR: 2.140, 95% CI: 1.254-3.653), FAB classification (favorable were reference, intermediate $p: 0.045$, HR: 2.269, 95% CI: 1.017-5.064, poor $p: 0.217$, HR: 2.105, 95% CI: 6.858) and HCT ($p: 0.034$, HR: 2.618, 95% CI: 1.073-6.387) were found as significant.

Conclusion: Progression free survival obtained after induction therapy and overall survival were relatively shorter than the ones which were presented by other real-world registries. Lack of early access to the targeted and novel agents, like Flt3 inhibitors, Venetoclax, IDH1 and 2 inhibitors, CPX351 and Glasdegib should be a potential explanation to this relatively short PFS and OS. We have also been aware of un-ideal access to well established and nation wide cytogenetic laboratory service to induce early integration of targeted agents to the treatment and better risk stratification to determine the patients who should obtain the best prolonged survival via allo-HCT.

Disclosures No relevant conflicts of interest to declare.

<https://doi.org/10.1182/blood-2023-182800>




Figure 1